TREM2 and cancer: For example, recent pre-clinical modelling demonstrates that triggering receptor expressed on myeloid cells 2 (TREM2) expression in TAMs in several cancers is associated with T-cell exhaustion and anti-PD1 therapy resistance,28,29 and TREM2 antibody therapy is being investigated in cancers with TAMs expressing this molecule,30 although TREM2 relevance in human glioblastoma is yet to be established.